DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions

Information source: Ranbaxy Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Topiramate (Drug)

Phase: N/A

Status: Completed

Sponsored by: Ranbaxy Laboratories Limited


The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg topiramate tablets following a 50 mg dose under fasting conditions.

Clinical Details

Official title: Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Bioequivalence evaluation of Topiramate 25mg tablets

Detailed description: This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult male volunteers and 4 alternates. All 28 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 24-hour blood draw. Subjects were to return for the 48-, 72-, 96- and 120-hour blood draws. Both periods were separated by a washout period of 14 days.


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.


Inclusion Criteria: 1. This study involved healthy adult male volunteers, 18-45 years of age, weighing at least 52 kg, who are within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983). 2. Only medically healthy subjects with clinically normal laboratory profiles were enrolled in the study. Exclusion Criteria: 1. History or presence of significant: • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease. In addition, history or presence of:

- Hypersensitivity or idiosyncratic reaction to topiramate

- Nephrolithiasis or gout

- Alcoholism or drug abuse within the past year

2. Subjects who had been on an abnormal diet (for whatever reason) during the 28 days preceding the study. 3. Subjects who had any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days of study start. 4. Subjects who had used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 28 days of study start. 5. Subjects who, through completion of the study, would have donated in excess of:

- 500 mL of blood in 14 days, or

- 500-750 mL of blood in 14 days (unless approved by the Principal Investigator),

- 1000 mL of blood in 90 days,

- 1250 mL of blood in 120 days,

- 1500 mL of blood in 180 days,

- 2000 mL of blood in 270 days,

- 2500 mL of blood in 1 year,

6. Subjects who had participated in another clinical trial within 28 days of study start.

Locations and Contacts

MDS Pharina Services (Clinical Research Center), St. Laurent, Québec H4R 2N6, Canada
Additional Information

Starting date: September 2001
Last updated: June 17, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017